Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

Inclusion Criteria:

- Women not of childbearing potential (WNOCBP) and males. Women must have documented
proof they are not of childbearing potential

- BMI of 20.0 to 38.0 kg/m2, inclusive

- Hepatic subjects classified as Child-Pugh mild (Class A) or Child-Pugh moderate (Class
B) who have had no significant change to disease status in past 6 months and are on
stable treatment regimen

- Healthy subjects must not have clinically significant deviations from normal in
medical history, physical exam, ECGs, vital signs or clinical lab values

Exclusion Criteria:

- Evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or
frequent unexplained bruising or thrombus formation

- Use of corticosteroids, nonsteroidal anti-inflammatory compounds, aspirin or other
antiplatelet agents or anticoagulants within 2 weeks of dosing

- Healthy subjects must not have used tobacco or have a history of drug or alcohol abuse
within the last 6 months

- Subjects must not have a current or recent (within 3 months) GI disease that increases
participant risk of GI bleeding or interferes with absorption of the study drug

Other protocol defined inclusion and exclusion criteria may apply